title: Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study.
abstract: OBJECTIVE
  To describe 12-month changes in choroidal thickness after anti-vascular endothelial growth factor (anti-VEGF) therapy for typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Prospective, consecutive, noninterventional, longitudinal case series.
  
  
  METHODS
  This study included patients with typical AMD and PCV who received anti-VEGF therapy over a 12-month period. We used spectral-domain optical coherence tomography with enhanced depth imaging mode to measure choroidal thickness.
  
  
  RESULTS
  Of the 163 patients, 77 had typical AMD and 86 had PCV. Patients with PCV were younger (67.6 vs 72.5 years, P < .01) and received fewer anti-VEGF injections (3.9 vs 5.6, P = .02) than patients with typical AMD. Baseline subfoveal choroidal thickness was not significantly different between PCV and typical AMD eyes, and was thicker in the study eye compared to fellow eye in the typical AMD group (223.1 vs 208.8 μm, P < .01). Subfoveal choroidal thickness decreased significantly in both typical AMD (213.7 μm to 190.3 μm, P < .001) and PCV (240.8 μm to 213.4 μm, P < .01) eyes, but no significant change was noted in fellow unaffected eyes. Reduction in choroidal thickness was associated with elevated C-reactive protein (odds ratio [OR]: 1.4, P = .04) and smoking (OR: 7.6, P = .03) at baseline, but not with age, refractive error, diagnosis of typical AMD or PCV, number or type of anti-VEGF injections, PDT therapy, or baseline choroidal thickness.
  
  
  CONCLUSIONS
  A significant reduction in subfoveal choroidal thickness was noted after anti-VEGF therapy in typical AMD and PCV. Choroidal thickness changes were similar despite differences in number of anti-VEGF treatment.
authors.affiliation: Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore.
authors.forename: Daniel Shu Wei
authors.initials: DS
authors.lastname: Ting
authors.affiliation: Singapore National Eye Centre, Singapore.
authors.forename: Wei Yan
authors.initials: WY
authors.lastname: Ng
authors.affiliation: Singapore National Eye Centre, Singapore.
authors.forename: Si Rui
authors.initials: SR
authors.lastname: Ng
authors.affiliation: Singapore Eye Research Institute, Singapore.
authors.forename: Shu Pei
authors.initials: SP
authors.lastname: Tan
authors.affiliation: Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore.
authors.forename: Ian Yew San
authors.initials: IY
authors.lastname: Yeo
authors.affiliation: Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore.
authors.forename: Ranjana
authors.initials: R
authors.lastname: Mathur
authors.affiliation: Singapore National Eye Centre, Singapore.
authors.forename: Choi Mun
authors.initials: CM
authors.lastname: Chan
authors.affiliation: Singapore National Eye Centre, Singapore.
authors.forename: Anna Cheng Sim
authors.initials: AC
authors.lastname: Tan
authors.affiliation: Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore.
authors.forename: Gavin Siew Wei
authors.initials: GS
authors.lastname: Tan
authors.affiliation: Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore.
authors.forename: Tien Yin
authors.initials: TY
authors.lastname: Wong
authors.affiliation: Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore. Electronic address: gemmy.cheung.c.m@snec.com.sg.
authors.forename: Chui Ming Gemmy
authors.initials: CM
authors.lastname: Cheung
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002829:Choroid / Q000473:pathology*; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011127:Polyps / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D012307:Risk Factors; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab